For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
When you’re hot, you’re hot: Studies of gut microbiome building by the day
+Print Archive
Pathology Update
When you’re hot, you’re hot: Studies of gut microbiome building by the day
Wednesday 27 March 2019, 08:45 AM

Pathology Update 2019 took place in Melbourne last month.
Key points, There are 10 times more bacteria than cells in the human body, and 29 per cent of all a person’s bacteria live in the gut.
The gut microbiome , MATT BROWN, Genomics leader Matt Brown sees great potential in gut microbial profiling for diagnosis and treatment
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
1. Almeida A, Mitchell AL, Boland M, et al. A new genomic blueprint of the human gut microbiota. Nature (online 11 February). https://go.nature.com/2SsFSL8
2. Costello M-E, Ciccia F, Willner D, et al. Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis & Rheumatology 2015;67;3:686–691.
3. Asquith M, Sternes PR, Costello M-E, et al. HLA alleles associated with risk of ankylosing spondylitis and rheumatoid arthritis influence the gut microbiome. bioRxiv (online 11 January). http://dx.doi.org./10.1101/517813